Co-Host: Brian Shuch, MD

At the conclusion of these activities, participants will be able to:

1. State the criteria for genetic testing of prostate cancer patients, the gene panels available, and options for testing these men.

2. Describe results of genetic testing and relay this information to patients in order to facilitate shared-decision making based on the test results.

3. Explain the importance of testing for germline mutations and their implication for novel therapies such as PARP inhibitors.

CME Available: https://auau.auanet.org/node/26054

This educational series is supported by independent educational grants from:

Amgen

Astellas

AstraZeneca

Bristol-Myers Squibb

Genomic Health

Merck

Pfizer, Inc.

Sanofi Genzyme

UroGen Pharma